We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ramucirumab’s Overall Survival Advantage Disappointing: Analysts
Eli Lilly’s cancer drug ramucirumab achieved a statistically significant but small overall survival advantage in a key gastric cancer trial, underwhelming analysts.